Page 2 - Peter Schmid News Today

Peter Schmid, FRCP, MD, PhD, discusses key findings from the phase 1/2 BEGONIA trial in patients with unresectable, metastatic or locally advanced triple-negative breast cancer, highlighting the clinical significance of these findings.

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 22, 2023--

Updated results from the BEGONIA Phase Ib/II trial for the cohort of patients treated with datopotamab deruxtecan plus Imfinzi showed that the combination demonstrated durable tumour...

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 22, 2023--

Treatment with neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy and followed by adjuvant pembrolizumab improved event-free survival compared with neoadjuvant chemotherapy alone in patients with high-risk triple-negative breast cancer.

Reverse Components has appointed Cyclorise as their official partner to distribute its products in the UK. Cyclorise replaces Fli Distribution as the - BikeBiz

Researchers are conducting a phase 1b/2 trial to compare durvalumab-based combinations in patients with metastatic triple-negative breast cancer.

A new moisturiser designed for dry winter skin has been dubbed the perfect everyday staple by physicians across the world.

Through digitally recreating the muscles of an early human ancestor, research has shed new light on how humans evolved to walk upright.

With pollen levels reaching record highs, patients with hay fever issues are also on the rise.